EPO and myelodysplastic syndrome: In a recent study using mesenchymal stem cells from young and old healthy individuals and patients with MDS, EPO treatment increased mineralization only in cells from young healthy individuals and not in cells from older healthy donors and cells from MDS patients (Balaian et al., 2018), suggesting that EPO bone remodeling activity may be age dependent.